ValiRx PLC KTH222 Evaluation Agreement Concluded (9600Z)
27 Mayo 2021 - 1:00AM
UK Regulatory
TIDMVAL
RNS Number : 9600Z
ValiRx PLC
27 May 2021
27 May 2021
VALIRX PLC
("ValiRx", the "Company" or the "Group")
KTH222 Evaluation Agreement Concluded
London, UK - ValiRx plc (AIM:VAL), a clinical stage drug
development company announces that further to the notification made
on 10 November 2020 it has concluded its agreement in relation to
the evaluation of the KTH222 peptide as a drug candidate announced
on 10 November 2020 for treating patients with ovarian cancer.
ValiRx announced on 10 November 2020 that it had entered into an
agreement with Kalos Therapeutics ("Kalos"), whereby ValiRx would
perform a range of preclinical evaluation experiments to determine
whether to enter a full licensing agreement for the therapeutic
candidate.
At the conclusion of the estimated six-month evaluation
schedule, ValiRx has elected to terminate the agreement and has
returned all data generated to Kalos.
Dr Suzy Dilly, Chief Executive Officer commented:
"The agreement with Kalos is a good example of our new strategy
to perform a considered yet straightforward assessment of best-fit
between scientific programmes and the Company. By identifying early
in this process that KTH222 is not a good strategic fit for our
pipeline, we have been able to return the asset to the originators
and continue our efforts to seek new science to bring into the
Company. We look forward to presenting the next new project to the
pipeline in due course."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
Ends
For further information please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
Optimum Strategic Communications Tel: +44 (0) 20 8148
Supriya Mathur/ Shabnam Bashir 3040
valirx@optimumcomms.com
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGREANSKASNFEFA
(END) Dow Jones Newswires
May 27, 2021 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024